Lupin Reshapes Business Lines: OTC and API Divisions Shift to Subsidiaries from July 1

Lupin Ltd has officially executed two major business transfers effective July 1, 2025, as part of its strategic restructuring to sharpen focus and unlock value across verticals.

 

The company has completed the slump sale of its Over-the-Counter (OTC) Consumer Healthcare business to its newly incorporated wholly owned subsidiary, LupinLife Consumer Healthcare Ltd (LCHL). The transfer, valued between ₹550–₹650 crore, includes a portfolio of high-performing wellness brands and is aimed at positioning LCHL as a standalone growth engine in India’s fast-expanding OTC market. The move allows Lupin to streamline its core prescription drug operations while giving LCHL the agility to scale independently.

 

Simultaneously, Lupin has transferred its API R&D division to another wholly owned subsidiary, Lupin Manufacturing Solutions Ltd (LMSL), also on a slump sale basis. The division, based at Lupin Research Park in Pune, contributed ₹230.3 million in revenue in FY24. The transfer is expected to enhance operational efficiency and support backward integration across Lupin’s global manufacturing network.

 

Both transactions were executed following Board approvals and regulatory disclosures made earlier this year. The company emphasized that these transfers are at arm’s length, with no promoter group involvement, and are in line with SEBI’s listing regulations.

 

These structural shifts reflect Lupin’s broader strategy to unlock value through focused subsidiaries, improve capital allocation, and drive long-term shareholder returns.

 

Sources: The Hindu BusinessLine, Business Standard, Lupin.com